ProCE Banner Activity

TOPAZ-1: Patient-Reported Outcomes From the Phase III Placebo-Controlled Trial of Durvalumab + Gemcitabine + Cisplatin for Advanced Biliary Tract Cancer

Slideset Download
Conference Coverage
In addition to a previously reported overall survival benefit, durvalumab + gemcitabine/cisplatin was associated with a trend toward longer time to deterioration in global health status/quality of life for patients with advanced biliary tract cancer vs placebo + gemcitabine/cisplatin.

Released: June 09, 2022

Expiration: June 08, 2023

No longer available for credit.


Provided by

Provided by Clinical Care Options, LLC
ProCE Banner


Supported by educational grants from



Bristol Myers Squibb

Daiichi Sankyo, Inc.

Gilead Sciences, Inc.


Jazz Pharmaceuticals Inc

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation

Seagen and Genmab